Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Vedanta Biosciences is raising $49,999,988.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Bernat Olle played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vedanta

Biosciences Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiology. We have pioneered the discovery of commensal gut bacteria involved in immune regulation and immune potentiation. Our issued patents broadly cover bacterial consortia drugs containing Clostridium organisms, one of the most abundant groups of bacteria in the gut. Our discovery platform enables identification of bacterial consortia with drug-like properties and their manufacture to GMP standards. To learn more about Vedanta Biosciences, visit http://www.vedantabio.com/

Contact:
Bernat Olle, Chief Executive Officer
857-706-1427
bolle@vedantabio.com
https://www.linkedin.com/in/bernat/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved